Catalyst down but not out on second trial failure of cocaine addiction drug
This article was originally published in Scrip
Executive Summary
Catalyst Pharmaceutical Partners lost 65.5% of its market value on 8 November based on the not particularly surprising news that CPP-109 (vigabatrin), its drug therapy for cocaine addiction, did not meet primary or secondary endpoints in a Phase IIb clinical trial.